Mark D. Booth
2009
In 2009, Mark D. Booth earned a total compensation of $3.2M as Chief Commercial Officer at Orexigen Therapeutics.
Compensation breakdown
| Bonus | $62,000 |
|---|---|
| Option Awards | $2,848,410 |
| Salary | $124,744 |
| Other | $200,115 |
| Total | $3,235,269 |
Booth received $2.8M in option awards, accounting for 88% of the total pay in 2009.
Booth also received $62K in bonus, $124.7K in salary and $200.1K in other compensation.
Rankings
In 2009, Mark D. Booth's compensation ranked 1,384th out of 9,885 executives tracked by ExecPay. In other words, Booth earned more than 86.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,384 out of 9,885 | 86th |
Division Manufacturing | 491 out of 3,690 | 87th |
Major group Chemicals And Allied Products | 101 out of 866 | 88th |
Industry group Drugs | 66 out of 638 | 90th |
Industry Pharmaceutical Preparations | 54 out of 446 | 88th |
Source: SEC filing on April 27, 2012.
Booth's colleagues
We found seven more compensation records of executives who worked with Mark D. Booth at Orexigen Therapeutics in 2009.
2009
Michael Narachi
Orexigen Therapeutics
Chief Executive Officer
2009
Preston Klassen
Orexigen Therapeutics
Head of Global Contrave Program and Senior Vice President, Product Development
2009
Dawn Viveash
Orexigen Therapeutics
Senior Vice President, Regulatory Affairs
2009
Graham Cooper
Orexigen Therapeutics
Chief Financial Officer
2009
Joseph Hagan
Orexigen Therapeutics
Chief Business Officer
2009
Heather Turner
Orexigen Therapeutics
General Counsel
2009
Eckard Weber
Orexigen Therapeutics